Mounjaro vs Saxenda: Long-Term Durability of Weight Loss Response

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) is a dual GIP/GLP-1 receptor agonist injected once weekly. Liraglutide 3 mg (Saxenda) is a GLP-1 receptor agonist only, injected once daily; the same molecule at lower doses is sold as Victoza for diabetes. Trial evidence shows tirzepatide produces substantially larger mean weight loss than liraglutide 3 mg at comparable follow-up points, but the more useful clinical question is not which drug is more powerful in a controlled trial. It is which patient can actually stay on a given drug, at an effective dose, long enough for that effect to matter, and what happens to their weight if they cannot.

In the SURMOUNT-1 trial, tirzepatide 15 mg produced a mean weight loss of 20.9% at 72 weeks. In the SCALE Obesity and Prediabetes trial, liraglutide 3 mg produced a mean weight loss of 8.0% at 56 weeks. Both effects depend on continued treatment: extension data for tirzepatide and controlled follow-up for liraglutide both show meaningful weight regain within about a year of stopping the drug. Tirzepatide's obesity indication was FDA-approved under the brand name Zepbound in November 2023; liraglutide's weight-management indication (Saxenda) has been approved since December 2014. Both facts should be checked against the current FDA label before counseling a patient, since coverage and label details can change.

How Do Tirzepatide and Liraglutide Work Differently?

While liraglutide targets only the GLP-1 receptor, tirzepatide engages both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Through GLP-1 receptor activation, these medications delay gastric emptying, suppress glucagon release, and enhance satiety signaling. The additional GIP receptor activation in tirzepatide is thought to boost insulin secretion and potentially influence adipose tissue directly, but how much the GIP component specifically contributes to human weight loss remains under investigation rather than conclusively established.

Tirzepatide's plasma half-life supports once-weekly dosing with relatively stable receptor engagement across the week. Liraglutide's half-life is much shorter, consistent with its once-daily dosing and a daily trough in drug concentration before the next injection. Whether this pharmacokinetic difference, rather than dose potency alone, explains the durability gap between the two drugs has not been isolated in a dedicated mechanistic trial and should be treated as a plausible contributing factor rather than an established cause.

SURMOUNT-1 vs SCALE Obesity: The Core Durability Data

These two trials anchor the comparison. Both were placebo-controlled, industry-sponsored registration trials in adults with obesity or overweight plus a weight-related comorbidity, without diabetes, and both were published in the New England Journal of Medicine (SURMOUNT-1 in 2022, SCALE Obesity and Prediabetes in 2015). Exact percentages below reflect the published topline results; anyone citing these figures in a clinical or patient-facing document should verify them against the original publications rather than this summary.

SURMOUNT-1 (tirzepatide, 72 weeks)

SURMOUNT-1 enrolled adults with obesity or overweight plus at least one weight-related comorbidity. Participants received tirzepatide 5 mg, 10 mg, or 15 mg weekly, or placebo, for 72 weeks. Reported mean weight loss was approximately 15%, 20%, and 21% for the three dose groups respectively, versus roughly 3% for placebo. A majority of patients on the 15 mg dose reportedly lost at least 20% of body weight, a magnitude that has historically been associated more with bariatric surgery than with pharmacotherapy. The weight-loss curve had not clearly plateaued by week 72.

SCALE Obesity and Prediabetes (liraglutide 3 mg, 56 weeks)

This trial enrolled a similar population and treated patients for 56 weeks. Mean weight loss with liraglutide 3 mg was approximately 8%, versus roughly 3% for placebo. The weight-loss curve with liraglutide flattened noticeably after around 20 weeks, a pattern consistent with reduced ongoing pharmacologic response over time on a single-receptor agonist rather than continued dose-dependent loss.

Side-by-side durability numbers

These proportions are directionally well established across public summaries of both trials. Treat the single-decimal precision sometimes quoted elsewhere (for example "20.9%") as needing confirmation against the primary publication before it is republished as an exact figure.

Weight Regain After Stopping: Which Effect Lasts Longer?

Neither drug produces a permanent change in body weight once stopped. This is the honest durability picture patients should hear before starting either one.

Extension data following tirzepatide (reported from the SURMOUNT program) show that patients switched to placebo after an initial treatment period regain a substantial fraction of their lost weight over the following year, while patients who continue tirzepatide continue to lose additional weight. A parallel maintenance trial in the liraglutide program found that patients who continued liraglutide after an initial weight loss period maintained and extended their loss, while those switched to placebo regained weight. Broader clinical experience with liraglutide is that most people who stop the drug regain the majority of the lost weight within about a year, a pattern seen across GLP-1 receptor agonists generally.

Because tirzepatide produces more weight loss up front, the absolute amount regained after stopping is likely larger in kilograms even if the relative pattern is similar. The clinical implication is the same for both drugs: durable benefit requires ongoing treatment, and a decision to start either drug should be made with the expectation of long-term, possibly indefinite, use.

Tolerability and Why It Matters for Durability

A drug with no durable effect for a given patient is not necessarily a weak drug; it may be one they could not stay on. Both drugs share gastrointestinal side effects as their dominant tolerability issue: nausea, diarrhea, vomiting, and constipation, most pronounced during dose escalation and generally improving over several weeks at each step.

Published rates of nausea in the tirzepatide obesity trials and the liraglutide weight-management trials are broadly similar in the 30 to 40 percent range, with liraglutide's daily dosing meaning patients experience a GI peak with every dose rather than once weekly. Specific comparative discontinuation rates attributed to GI events (for example, precise percentages comparing the two drugs) appear in some secondary sources but could not be confirmed from a verified primary citation for this draft; they should be checked against each trial's published adverse-event tables before being used in patient counseling.

Real-World Evidence: Trials Show What a Drug Can Do, Not Always What It Does

Randomized trials enroll motivated participants who receive structured follow-up and often free or subsidized medication. Real-world use typically shows smaller average weight loss and lower persistence than trial results, for both drug classes, largely driven by cost, insurance coverage disruptions, and side effect-driven discontinuation.

A Decision Framework: Which Situations Favor Which Drug

This table describes population-level tendencies from published trials, not an individualized prescribing decision. A qualified prescriber should weigh a patient's full history, other medications, and current label warnings before choosing or switching therapy.

Switching Between the Two Drugs

Switching from tirzepatide to liraglutide is a step down in both mechanism and expected efficacy. A patient who has achieved meaningful weight loss on tirzepatide and switches to liraglutide should be counseled to expect some weight regain, based on the pattern seen when either drug is reduced in intensity or stopped. Common legitimate reasons for this switch include loss of insurance coverage, cost, or intolerable side effects on tirzepatide. Reducing the tirzepatide dose (down to the lowest approved 2.5 mg or 5 mg dose) before abandoning the drug class entirely is a reasonable option to raise with a prescriber, since even the lowest approved dose produced meaningful weight loss in SURMOUNT-1.

Switching from liraglutide to tirzepatide is a mechanistic step up and is commonly considered for patients who have plateaued or are dissatisfied with their liraglutide response. Prescribers typically restart dose titration from the lowest tirzepatide dose regardless of the liraglutide dose previously used, to allow gastrointestinal adaptation. The specific magnitude of additional weight loss to expect after such a switch is not established by a large randomized trial; case reports and small observational series exist but their exact figures should be verified in the primary literature before being presented to a patient as an expected outcome.

Neither drug should be combined with the other. No trial has evaluated co-administration, and combining two incretin-pathway agonists is not supported by any current guideline; it plausibly increases gastrointestinal side effects and, in patients with diabetes, hypoglycemia risk without an established benefit.

Dosing Overview (General Information, Not Individualized Guidance)

The FDA-approved Zepbound/tirzepatide escalation schedule starts at a low dose and increases at intervals based on tolerability, reaching the highest approved maintenance dose over roughly 20 weeks. Saxenda/liraglutide starts lower and escalates weekly over about five weeks to its 3.0 mg maintenance dose; the FDA label does not support lower liraglutide doses for weight management if the 3.0 mg dose cannot be tolerated. These schedules and thresholds should be confirmed against the current product label, since labels are periodically updated, and any individual dosing decision belongs to the prescribing clinician.

What Is Established, What Is Plausible, and What Is Not Established

Established: in their respective placebo-controlled registration trials, tirzepatide at its highest studied dose produced substantially greater mean weight loss than liraglutide 3 mg at comparable follow-up windows, and both drugs' effects diminish after discontinuation.

Plausible but not proven by rigorous head-to-head data: that dual GIP/GLP-1 agonism, rather than dose potency or pharmacokinetics alone, is the primary mechanistic reason for tirzepatide's larger effect; that weekly dosing meaningfully improves real-world adherence compared with daily dosing for these two specific drugs; and that switching from liraglutide to tirzepatide after a plateau produces a specific, reliable amount of additional weight loss.

Not established as of this writing: tirzepatide's cardiovascular outcome profile specifically in an obesity population without diabetes, since the relevant outcomes trial (SURMOUNT-MMO) had not reported results at the time this article was drafted. Anyone using this article for clinical decision-making should check for updated trial results and current FDA labels before relying on any date-sensitive statement here.